Trajectories of forced vital capacity in patients with systemic sclerosis-associated interstitial lu...
Trajectories of forced vital capacity in patients with systemic sclerosis-associated interstitial lung disease
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
We used data from the SENSCIS and SENSCIS-ON trials to assess decline in forced vital capacity (FVC) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) who received long-term treatment with nintedanib and the effect of switching patients from placebo to nintedanib. In the SENSCIS trial, patients were randomised to re...
Alternative Titles
Full title
Trajectories of forced vital capacity in patients with systemic sclerosis-associated interstitial lung disease
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_046faeaae059495c8b81ac6df66fae89
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_046faeaae059495c8b81ac6df66fae89
Other Identifiers
ISSN
1478-6362,1478-6354
E-ISSN
1478-6362
DOI
10.1186/s13075-025-03524-9
